Alterity Therapeutics (ATHE) Total Non-Current Liabilities (2015 - 2025)
Alterity Therapeutics' quarterly Total Non-Current Liabilities came in at $42980.1 in Q4 2025, up 52.43% year-on-year from $28197.3 in Q4 2024, and down 24.21% quarter-over-quarter from $56707.2 in Q2 2025.
Alterity Therapeutics has reported Total Non-Current Liabilities for 11 years, with the latest figure at $42980.1 in Q4 2025.
- For the quarter ending Q4 2025, Total Non-Current Liabilities rose 52.43% year-over-year to $42980.1; the trailing twelve-month figure through Dec 2025 stood at $42980.1 (up 52.43% YoY), and the FY2025 full-year result was $56707.2, up 65.75% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at $42980.1, down from $56707.2 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $56707.2 in Q2 2025, with the low at -$1.2 million in Q2 2024.
- Average Total Non-Current Liabilities over 5 years is -$82282.5, with a median of $33909.0 recorded in 2022.
- Year-over-year, Total Non-Current Liabilities surged 388.34% in 2021 and plunged 93911.18% in 2024.
- Tracing ATHE's Total Non-Current Liabilities over 5 years: stood at $28873.4 in 2021, then grew by 7.74% to $31108.7 in 2022, then jumped by 60.1% to $49804.0 in 2023, then plunged by 43.38% to $28197.3 in 2024, then surged by 52.43% to $42980.1 in 2025.
- The last three Total Non-Current Liabilities figures came in at $42980.1 (Q4 2025), $56707.2 (Q2 2025), and $28197.3 (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 746.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 42,980.09 |
| Jun 30, 2025 | 56,707.16 |
| Dec 31, 2024 | 28,197.30 |
| Jun 30, 2024 | -1.15 Mn |
| Dec 31, 2023 | 49,804.03 |
| Jun 30, 2023 | 1,227.10 |
| Dec 31, 2022 | 31,108.67 |
| Jun 30, 2022 | 52,724.51 |
| Dec 31, 2021 | 28,873.40 |
| Jun 30, 2021 | 36,709.30 |
| Dec 31, 2020 | 5,912.53 |
| Jun 30, 2020 | 27,778.04 |
| Dec 31, 2019 | 32,731.58 |
| Jun 30, 2019 | 24,499.72 |
| Dec 31, 2018 | 0.93 |
| Jun 30, 2018 | 693.45 |
| Dec 31, 2017 | 480.65 |
| Jun 30, 2017 | 0.30 |
| Dec 31, 2016 | 347.32 |
| Jun 30, 2016 | 0.37 |
| Dec 31, 2015 | 454.12 |
| Jun 30, 2015 | 1.87 |